A review on recent trends of diabetes mellitus
Abstract
Type 2 diabetes mellitus is a chronic metabolic disorder in which has been increasing all over the world. The epidemic nature of diabetes mellitus in different regions is reviewed. Whereas the Middle East and North Africa region has the highest prevalence of diabetes.it highlights a growing epidemic imposing serious social-economic crisis to the countries around the globe. This review is based on some trending therapeutic and technological methods and a few current trending medications such as newly launched oral drugs and injectable drugs like glyxambi, segluromet, tresiba, ozempic, etc. these are helpful to manage your diabetes. Lifestyle plays a crucial role in the management of diabetes. Some major lifestyles are nutritional diet and exercises etc.
Keywords:
diabetes mellitus, social-economic crisis, trending therapeutics
Downloads
Download data is not yet available.
References
1. Atkinson MA, Eisenbarth GS. Type 1 diabetes new perspectives on disease pathogenesis and treatment, Lancet. 2001; 358:221-229.
2. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition and diabetes in the tropics, Diabetes Care. 1996; 19:1014- 17,
3. Tripathy BB, Samal KC. Overview and consensus statement on diabetes in tropical areas, Diabetes Metab Rev. 1997; 13:63-76.
4. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB, Monsciotti CM et al., Clinical and subclinical organ– specific autoimmune manifestations in type 1 (insulin– dependent) diabetic patients and their first-degreerelatives, Diabetologia. 1983; 26:431-36.
5. Bearse MA Jr, Han Y, Schneck ME, Barez S, Jacobsen C. Localmultifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy, Invest Ophthalmol Vis Sci. 2004; 45:3259-3265.
6. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles W, Cohen M et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency, Diabetic Med. 1994; 11:299-303.
7. Bastaki S., “Diabetes mellitus and its treatment”,International Journal of Diabetes and Metabolism2005; 13:111-134.
8. Baynest H.W., “Classification, pathophysiology,diagnosis and management of diabetes mellitus”.Journal of Diabetes and Metabolism 2015; 6:5.
9. Siddiqui A.A., Siddiqui S.A., Ahmad S, Siddiqui S,Ahsan I. and Sahu K., “Diabetes: mechanism,pathophysiology and management- A review”.InternationalJournal of Drug Development andResearch 2013; 5(2):1-23.
10. Madras Diabetes Research Foundation (India), 2014, http:// mdrf.in/.
11. J. B. Buse, “Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy,” Diabetes Care, vol. 22, pp. 65–70, 1999.
12. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications, World Health Organization, Department of Non Communicable Disease Surveillance, Geneva, Switzerland, 1999. [27] American Diabetes Association, “Gestational diabetes mellitus,” Diabetes Care, vol. 23, pp. 77–79, 2000. [28] L. Jovanovic and D. J. Pettitt, “Gestational diabetes mellitus,”The 13.Journal of the American Medical Association, vol. 286, no. 20, pp. 2516–2518, 2001. [29] D. Coustan, “Gestational diabetes,” in Diabetes in America, M. I. Harris, C. C. Cowie, M. P. Stern, E. J. Boyko, G. E. Reiber, and P. H. Bennett, Eds., pp. 703–717, U.S. Government Printing Office, Washington, DC, USA, 2nd edition, 1995.
14. Ahmed AM. History of diabetes mellitus. Saudi Med J 2002 Apr; 23(4):373-37
15. Diabetes mellitus history- from ancient to modern times. Available at http://science.jrank.org/pages/2044/Diabetes-Mellitus.html. (Accessed on 22ndJuly, 2011)
16. Patlak M. New weapons to combat an ancient disease: treating diabetes.FASEB J 2002 Dec; 16(14):1853.
17.Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998 Mar; 47(3):345-351.
18. Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006 Apr; 32(2):113-120.
46. Yki-jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11):1106-1118. 47. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995 May; 98(5):443-451.
19. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 May; 373(9675):1607-1614.
20. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies.J Diabetes 2011. (Published online ahead of print).
2. Hoet JJ, Tripathy BB, Rao RH, Yajnik CS. Malnutrition and diabetes in the tropics, Diabetes Care. 1996; 19:1014- 17,
3. Tripathy BB, Samal KC. Overview and consensus statement on diabetes in tropical areas, Diabetes Metab Rev. 1997; 13:63-76.
4. Betterle C, Zanette F, Pedini B, Presotto F, Rapp LB, Monsciotti CM et al., Clinical and subclinical organ– specific autoimmune manifestations in type 1 (insulin– dependent) diabetic patients and their first-degreerelatives, Diabetologia. 1983; 26:431-36.
5. Bearse MA Jr, Han Y, Schneck ME, Barez S, Jacobsen C. Localmultifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy, Invest Ophthalmol Vis Sci. 2004; 45:3259-3265.
6. Zimmet PZ, Tuomi T, Mackay R, Rowley MJ, Knowles W, Cohen M et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency, Diabetic Med. 1994; 11:299-303.
7. Bastaki S., “Diabetes mellitus and its treatment”,International Journal of Diabetes and Metabolism2005; 13:111-134.
8. Baynest H.W., “Classification, pathophysiology,diagnosis and management of diabetes mellitus”.Journal of Diabetes and Metabolism 2015; 6:5.
9. Siddiqui A.A., Siddiqui S.A., Ahmad S, Siddiqui S,Ahsan I. and Sahu K., “Diabetes: mechanism,pathophysiology and management- A review”.InternationalJournal of Drug Development andResearch 2013; 5(2):1-23.
10. Madras Diabetes Research Foundation (India), 2014, http:// mdrf.in/.
11. J. B. Buse, “Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy,” Diabetes Care, vol. 22, pp. 65–70, 1999.
12. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications, World Health Organization, Department of Non Communicable Disease Surveillance, Geneva, Switzerland, 1999. [27] American Diabetes Association, “Gestational diabetes mellitus,” Diabetes Care, vol. 23, pp. 77–79, 2000. [28] L. Jovanovic and D. J. Pettitt, “Gestational diabetes mellitus,”The 13.Journal of the American Medical Association, vol. 286, no. 20, pp. 2516–2518, 2001. [29] D. Coustan, “Gestational diabetes,” in Diabetes in America, M. I. Harris, C. C. Cowie, M. P. Stern, E. J. Boyko, G. E. Reiber, and P. H. Bennett, Eds., pp. 703–717, U.S. Government Printing Office, Washington, DC, USA, 2nd edition, 1995.
14. Ahmed AM. History of diabetes mellitus. Saudi Med J 2002 Apr; 23(4):373-37
15. Diabetes mellitus history- from ancient to modern times. Available at http://science.jrank.org/pages/2044/Diabetes-Mellitus.html. (Accessed on 22ndJuly, 2011)
16. Patlak M. New weapons to combat an ancient disease: treating diabetes.FASEB J 2002 Dec; 16(14):1853.
17.Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998 Mar; 47(3):345-351.
18. Blicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006 Apr; 32(2):113-120.
46. Yki-jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11):1106-1118. 47. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995 May; 98(5):443-451.
19. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 May; 373(9675):1607-1614.
20. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies.J Diabetes 2011. (Published online ahead of print).
Published
06/01/2022
Statistics
1498 Views | 897 Downloads
Citatons
How to Cite
A, T. R., Basu, V. R., G, S., A, S., & N, S. S. R. (2022). A review on recent trends of diabetes mellitus. Journal of Innovations in Applied Pharmaceutical Science (JIAPS), 7(1), 01-09. https://doi.org/10.37022/jiaps.v7i1.258
Issue
Section
Review Article(S)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.